We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not on my screen Shatter. Down 6.5%.
Really in the doldrums now.
K
Alliance News) - Oxford BioMedica PLC on Tuesday reported a drop in annual revenue and swung to a loss, as a result of lower volumes and higher costs.
The Oxfordshire, England-based gene and cell therapy group posted revenue of GBP140.0 million in 2022, down from GBP142.8 million a year ago. It swung to a pretax loss of GBP46.0 million from a profit of GBP19.9 million.
And it’s up nearly 3% ?. Go figure
I know the market is in meltdown today but why has this fallen so far. Delayed LSE has it below £500 at 9% down. Surely the BOD must say something even if it is we don't understand why it has fallen so sharply and steeply?
I don't like to get over optimistic with this one,however it is showing signs of recovery.
I'm almost frightened to say anything as this is a very welcome rise seemingly on the back of the announcement of the new CEO as I can't find any other news. Long way to go yet but encouraging
S.P. usually gets twitchy around the fiver..
https://www.bbc.co.uk/news/health-64629680
I'm assuming that the drug, Libmeldy, developed by Orchard Therpeutics would have used OXB's LentiStable™ technology (the "harmless virus").
Nice rise today…
When are people going to realise that OXB is not just another Covid vaccine stock? Yes, OXB made money during Covid using its manufacturing facilities but OXB is not simply about Covid vaccines. OXB manufactures "drug delivery systems" and was simply in the right place, at the right time, to take advantage of the need for Covid vaccines but its manufacturing facilities were not built for Covid and there's a lot more to potentially come.
It keeps trying to move up but is always knocked back. Still hopeful I will get my money back but fear the £15 days are long gone.
Well, what could possibly go wrong?
50%up in the last 10 weeks, can only be good
Great to see the sp rising again…
Pure speculation, but China is having COVID epidemic. It's own vaccines are not as successful as others. Oxb is a company that can produce Astra Zeneca vaccine by the aircraft load.
This thought must have occurred to more than an investor like me at the very bottom of the feeding chain. So just maybe....
Up and down like a fiddlers elbow…
Not a water leak.
Oxb’s favourite word. The market is not impressed.
7% ?
Indeed and the recent little rise hasn't lasted long either.
Only Scancell of my bios doing ok atm. Surprisingly it seems a sector out of favour.
Analysts at Liberum cut their target price for shares Oxford Biomedica from 1,390.0p to 1,010.0p on Monday, arguing that the company's pan-vector offering had yet to reach sufficient scale in order to deliver sustainable profitability.
If only…..
or at least not very negative which is a blessing with this share atm
New CEO, looks like a good appointment. Opening markets positive
They will burn through that 60 million and then fail to make rent and get evicted. I also heard they plan to axe innovation teams so this is likely a first step towards that because they will lose their labs when they lose Windrush. There is some office space at manufacturing sites in Oxbox and Yarnton, so I imagine that's where all the core business staff and manufacturing directors will end up in the streamlined CDMO business.
The share price doesn’t stand a chance when you see the trades going through. This is being manipulated by bots and has been for months…
Half Oxb’s value is now in cash but the upside is they shouldn’t need to raise any funds for a while.
Shatter
I read your comment before the RNS and thought for one moment it was a deal for its products, licensing or something. Not a fan of sale and leaseback but it can make sense if you are cash strapped. Assuming they last the full 15 years OXB will pay something like £68m in rent which if you factor in possible future inflation and do a discounted cash flow (which I am not) I guess will be less than what they have received but they will of course not own the asset. We also don't know the terms of the lease - who is responsible for maintenance and upgrading as today's facilities will not be fir for purpose in 10 years time.
So I am neutral on this unless the funds are put to a use that increases the value of the sp I can't see this in itself doing much for it. I hope I am wrong and we move rapidly out of the £3 arena